Despite significant advances in the treatment of hematological malignancies over the previous decades, morbidity and mortality from theses disorders still remain high. New discoveries in the pathways involved in the pathophysiology led to new thinking in drug discovery. mTOR inhibitors are new and viable options for patients with these malignancies. We hope that newer clinical data will bring about new options in this field.
|Original language||English (US)|
|Number of pages||17|
|Journal||Current Problems in Cancer|
|State||Published - Jul 1 2008|
ASJC Scopus subject areas
- Cancer Research